Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 - Blanke, C D; Rankin, C; Demetri, G D (J Clin Oncol, 2008)
, et al.